Rigel Pharmaceuticals, Inc.
$40.09-$1.10 (-2.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $559.7M
- P/E
- 1.5x
- EV / EBITDA
- 4.4x
- Revenue
- $294.3M
- Net margin
- 124.7%
- ROCE
- 30.3%
Price chart
Technical chartScreen technicals →-8.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -16.7%
- 3M
- -11.4%
- 6M
- +39.1%
- 1Y
- -8.6%
- 5Y
- Hidden
- This period includes a one-day price step on 8 Jun 2022 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.
52-week range
Day change -$1.10 (-2.7%) from $41 to $40 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in RIGL, bought on each weekday since 2021.
News & filings
What Rigel Pharmaceuticals filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthReturn on equity of 93.8%.
Concerns (1)
- Operating cash flow was 0.21 times net profit in fiscal 2025.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States.
Read moreShow less
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor, which is being advanced to Phase 1b study for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. The company has strategic development collaboration with The University of Texas MD Anderson Cancer Center (MDACC) for the development of olutasidenib in AML and other hematologic cancers with IDH1mutations; and the Collaborative Network for Neuro-Oncology Clinical Trial (CONNECT) to conduct a Phase 2 clinical trial to evaluate olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
- Sector
- Healthcare
- Shares outstanding
- 18.0M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $559.7M
- P/E
- 1.5x
- P/B
- 1.4x
- EV / EBITDA
- 4.4x
- EV / Sales
- 1.9x
- P/S
- 1.9x
- 52-week high
- $51.45
- 52-week low
- $25.44
Profitability
- Operating margin
- 42.6%
- Net margin
- 124.7%
- EBITDA margin
- 44.7%
- ROE
- 93.8%
- ROCE
- 30.3%
- ROIC
- 32.0%
- ROA
- 71.5%
- Asset turnover
- 0.57
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $294.3M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 64.1%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 34.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 1999.1%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $75.7M
Solvency
- Current ratio
- 2.42
- Debt / Equity
- 0.14
- Debt / Assets
- 0.10
- CFO / Net profit
- 0.21
- Cash / Market cap
- 7.3%
Where the revenue went
Of every $100 of FY2025 revenue, $125 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $19.6M |
| Revenue | Gross profit | $274.7M |
| Gross profit | Operating expenses | $149.2M |
| Gross profit | Operating income | $125.5M |
| Operating income | Pretax income | $121.8M |
| Operating income | Interest and other expense | $3.6M |
| Pretax income | Net income | $121.8M |
| Tax benefit and other | Net income | $245.2M |
Revenue and net profit
Revenue grew 64.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $120.2M | -$58.6M |
| FY2023 | $116.9M | -$25.1M |
| FY2024 | $179.3M | $17.5M |
| FY2025 | $294.3M | $367.0M |
Cash flows
FY2025: $75.7M from operations, $75.7M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$73.8M | -$74.2M |
| FY2023 | -$5.7M | -$20.7M |
| FY2024 | $31.5M | $31.1M |
| FY2025 | $75.7M | $75.7M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $294.3M+64.1%1Y
- EBITDA
- $131.6M+361.4%1Y
- Net profit
- $367.0M+1,999.1%1Y
- Cash from operations
- $75.7M+140.4%1Y
- Free cash flow
- $75.7M+143.5%1Y
- Revenue CAGR, 3Y
- 34.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $294.3M | $131.6M | $367.0M | $75.7M | 93.8% | +64.1% | +1999.1% |
Monthly returns
Month-by-month returns of RIGL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $513.6M |
| Current assets | $240.2M |
| Non-current assets | $273.4M |
| Liabilities | $122.1M |
| Current liabilities | $99.2M |
| Non-current liabilities | $22.9M |
| Equity | $391.5M |
| Paid-in capital | $1.4B |
| Retained earnings | -$1.0B |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; RIGL highlighted.
P/E against peers
RIGL trades at 1.5x earnings against a peer median of -6.4x.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Rigel Pharmaceuticals, Inc.RIGLthis company | $559.7M | 1.5x | 1.4x | 93.8% | 4.4x |
| Altimmune, Inc.ALT | $567.9M | -6.4x | 2.5x | -39.2% | -6.4x |
| Tactile Systems Technology, Inc.TCMD | $567.7M | 29.7x | 2.6x | 8.7% | 12.4x |
| MiMedx Group, Inc.MDXG | $563.0M | 11.6x | 2.2x | 18.9% | 5.3x |
| Ironwood Pharmaceuticals, Inc.IRWD | $559.7M | 23.3x | -2.1x | -9.2% | 9.0x |
| Cytek Biosciences, Inc.CTKB | $559.2M | -8.4x | 1.6x | -19.5% | -28.3x |
| Cerus CorporationCERS | $559.0M | — | 8.7x | -24.3% | — |
| NeuroPace, Inc.NPCE | $556.4M | -25.9x | 29.2x | -112.8% | -50.2x |
| Fulgent Genetics, Inc.FLGT | $553.8M | -9.2x | 0.5x | -5.4% | -11.2x |
| Peer median | — | -6.4x | 2.4x | -14.3% | -6.4x |
Year-to-date ROI
RIGL since 1 January, against earlier years.
Historical volatility
RIGL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -45.1% |
| FY2023 | -17.5% |
| FY2024 | 13.5% |
| FY2025 | 42.6% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $294.3M |
| Cost of revenueCost Of Revenue | $19.6M |
| Gross profitGross Profit | $274.7M |
| Operating expensesOperating Expense | $149.2M |
| Research and developmentResearch And Development | $33.3M |
| Selling, general and administrativeSelling General And Administration | $115.9M |
| Total expensesTotal Expenses | $168.8M |
| Operating incomeOperating Income | $125.5M |
| Interest and other | |
| Pretax incomePretax Income | $121.8M |
| TaxTax Provision | -$245.2M |
| Net incomeNet Income | $367.0M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $513.6M |
| Current assetsCurrent Assets | $240.2M |
| Non-current assetsTotal Non Current Assets | $273.4M |
| LiabilitiesTotal Liabilities Net Minority Interest | $122.1M |
| Current liabilitiesCurrent Liabilities | $99.2M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $22.9M |
| EquityTotal Equity Gross Minority Interest | $391.5M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $75.7M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $75.7M |
| Net income, continuing operationsNet Income From Continuing Operations | $367.0M |
| Depreciation and amortisationDepreciation And Amortization | $2.4M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $2.4M |
| Amortization of securitiesAmortization Of Securities | -$1.1M |
| Stock-based compensationStock Based Compensation | $12.7M |
| Deferred taxDeferred Tax | -$245.8M |
| Deferred income taxDeferred Income Tax | -$245.8M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | $0.00 |
| Change in working capitalChange In Working Capital | -$19.5M |
| Other non-cash itemsOther Non Cash Items | -$40.0M |
| Investing cash flowInvesting Cash Flow | -$92.4M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$92.4M |
| Capital expenditureCapital Expenditure | — |
| Capital expenditure (reported)Capital Expenditure Reported | $0.00 |
| Purchase of PP&EPurchase Of PPE | — |
| Sale of PP&ESale Of PPE | $0.00 |
| Net PP&E purchases and salesNet PPE Purchase And Sale | $0.00 |
| Purchase of investmentsPurchase Of Investment | -$153.5M |
| Sale of investmentsSale Of Investment | $61.1M |
| Net investment purchases and salesNet Investment Purchase And Sale | -$92.4M |
| Purchase of intangiblesPurchase Of Intangibles | $0.00 |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | $0.00 |
| Financing cash flowFinancing Cash Flow | $600.0k |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $600.0k |
| Debt issuedIssuance Of Debt | $0.00 |
| Debt repaidRepayment Of Debt | -$7.5M |
| Net debt issuedNet Issuance Payments Of Debt | -$7.5M |
| Long-term debt issuedLong Term Debt Issuance | $0.00 |
| Long-term debt repaidLong Term Debt Payments | -$7.5M |
| Net long-term debt issuedNet Long Term Debt Issuance | -$7.5M |
| Net common stock issuedNet Common Stock Issuance | $0.00 |
| Common stock repurchasedCommon Stock Payments | $0.00 |
| Share buybacksRepurchase Of Capital Stock | $0.00 |
| Stock options exercisedProceeds From Stock Option Exercised | $8.1M |
| Other financing chargesNet Other Financing Charges | — |
| Change in cashChanges In Cash | -$16.1M |
| Cash at the start of the yearBeginning Cash Position | $56.8M |
| Cash at the end of the yearEnd Cash Position | $40.6M |
| Free cash flowFree Cash Flow | $75.7M |
| Supplemental |
Learn while you research
Academy chapters picked for Rigel Pharmaceuticals, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Value InvestingA P/E of 1.5 could be a value opportunity, or a value trap. Know the difference.7 min read
- 03 Growth Investing64% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 05 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 06 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read